Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Quizartinib Poised to Expand FLT3 Inhibition Options in AML

April 16th 2019

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Direct Oral Anticoagulants Signal Change in VTE Prevention

April 16th 2019

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

March 21st 2019

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Tumor Marker Trial Aims to Ease "Scanxiety" in Breast Cancer

March 5th 2019

Breast surveillance is essential when determining whether or not therapy is beneficial and to avoid toxicity, usual care for patients with metastatic breast cancer includes monitoring of symptoms and cancer burden.

New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma

March 4th 2019

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

Study Tests Preoperative Therapy for Easing Resection Burden in Rare Cancer

February 19th 2019

A recently launched clinical trial aims to improve outcomes and quality of life for patients with nasal and paranasal squamous cell carcinoma (NPNSCC), a rare type of head and neck cancer that is challenging to treat and carries significant morbidity.

Combos and Biomarkers Will Shape the Future of Bladder Cancer Immunotherapy

February 1st 2019

Although multiple checkpoint inhibitors have been introduced into the bladder cancer treatment paradigm during the past several years, their use in the malignancy remains an unfolding story.

Duvelisib Provides CLL Patients With a Later Line of Therapy

January 24th 2019

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

NCI Moves to Expand Clinical Trial Eligibility Criteria

January 22nd 2019

In en effort to ensure that study participants are more reflective of real-world populations, the National Cancer Institute has revised its clinical trial protocols to expand access for previously excluded patients.

MyDRUG Evaluates Targeted Agents in Multiple Myeloma

January 16th 2019

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.

Study Finds No Cognitive Effects From Endocrine Therapy

January 8th 2019

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

Real-World irAEs May Be Higher Than Trial Data Indicate

December 18th 2018

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.